Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alprazolam is a fast-acting, high-potency triazolobenzodiazepine used primarily for the treatment of anxiety disorders and panic disorder, including anxiety associated with depression. It acts as a central nervous system depressant by binding to the benzodiazepine site on the GABA A receptor complex in the brain, enhancing the inhibitory effects of gamma aminobutyric acid (GABA). This results in decreased abnormal excitement and produces anxiolytic, anticonvulsant, muscle relaxant, hypnotic, and amnesic effects. Alprazolam is metabolized mainly by CYP3A enzymes and should not be used with strong CYP3A inhibitors. It was first approved by the FDA in 1981 and is available only by prescription[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam.